Zydowsky Lynne 4
4 · YUMANITY THERAPEUTICS, INC. · Filed Dec 28, 2020
Insider Transaction Report
Form 4
Zydowsky Lynne
Director
Transactions
- Award
Stock Option (Right to Buy)
2020-12-22+12,495→ 12,495 totalExercise: $8.16Exp: 2029-12-15→ Common Stock (12,495 underlying) - Award
Stock Option (Right to Buy)
2020-12-22+5,271→ 5,271 totalExercise: $8.16Exp: 2030-04-06→ Common Stock (5,271 underlying)
Footnotes (5)
- [F1]On August 22, 2020, the Issuer (formerly known as Proteostasis Therapeutics, Inc.) entered into an Agreement and Plan of Merger and Reorganization, as amended on November 6, 2020, with Pangolin Merger Sub, Inc. ("Merger Sub"), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) and Yumanity Holdings, LLC ("Holdings"). On December 22, 2020, Merger Sub was merged with and into Yumanity, Inc., with Yumanity, Inc. surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the consummation of the Merger, Holdings was merged with and into Yumanity, Inc., with Yumanity, Inc. as the surviving entity.
- [F2]The shares subject to the option vest in equal quarterly installments over four years, commencing on October 1, 2019.
- [F3]Received in the Merger in exchange for a stock option to acquire 59,266 shares of Yumanity, Inc. common stock for $1.72 per share.
- [F4]The shares subject to the option vest in equal quarterly installments over four years, commencing on February 18, 2020.
- [F5]Received in the Merger in exchange for a stock option to acquire 25,000 shares of Yumanity, Inc. common stock for $1.72 per share.